Truist Securities increased its price target for Exelixis (NASDAQ:EXEL) shares to $43.00, up from the previous target of $42.00, while reaffirming a Buy rating on the stock. The new target represents ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...

JMP Securities maintained a positive stance on Exelixis (NASDAQ:EXEL) stock, reiterating a Market Outperform rating with a ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of ...

A major downgrade, a billion-dollar pipeline gamble, and a patent war--Exelixis investors brace for a wild ride.

Park Avenue Securities LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and ...

Oppenheimer shifts to a neutral stance on Exelixis, questioning differentiation between zanzalintinib and cabozantinib ...

On Friday, Exelixis Inc (EXEL) stock saw a decline, ending the day at $32.38 which represents a decrease of $-1.75 or -5.13% from the prior close of $34.13. The stock opened at $33.49 and touched a ...

Exelixis (NASDAQ:EXEL – Get Free Report) had its price target raised by research analysts at Truist Financial from $38.00 to ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $34.13 which represents a slight increase of $1.25 or 3.80% from the prior close of $32.88. The stock opened at $33 and touched a low ...

Exelixis, Inc. EXEL announced its preliminary financial results for fiscal 2024 and provided guidance for fiscal 2025. Revenues, on a preliminary basis, for 2024 were approximately $2.165 billion ...

EXEL designs advanced medicines and regimens to battle cancer. Its product portfolio focuses on an expanding range of tumors, ...